Developing a new urine cell flow cytometry analysis of pdl1 expression and DNA content for diagnosis of bladder cancer
Recommended Citation
Alanee SR, Deebajah M, Chen P, Wang X, and Patterson BK. Developing a new urine cell flow cytometry analysis of pdl1 expression and DNA content for diagnosis of bladder cancer. J Clin Oncol 2019; 37.
Document Type
Conference Proceeding
Publication Date
10-2019
Publication Title
J Clin Oncol
Abstract
Background: Bladder cancer is the fifth most common cancer in the United States. PD1/PDL1, a pathway used by cancer cells to evade immune response, correlates with bladder cancer severity and has emerged as a target in bladder cancer treatment. Chromosomal instability is also a prominent feature associated with the development of bladder cancer. A method for unbiased analysis of PDL1 expression and DNA content in cells from urine samples promises to be a new test for diagnosis of bladder cancer. Methods: To evaluate the PDL1 expression and DNA content, we developed a 4color flow assay. Cells in voided urine samples were pelleted, fixed in incellMAX (IncellDx Inc.) and stained with antibodies against pancytokeratin (CK), CD45, PDL1 and a cell cycle dye. The stained samples were analyzed by a flow cytometer alongside stained control cells. Results: Fifty bladder cancer patient and 15 normal donor urine samples were collected and tested with this assay. We could distinguish epithelial cells (panCK+) and white blood cells (WBCs, CD45+) in urine samples and obtain PDL1 expression and DNA content information simultaneously from these cell populations. The patient samples showed a significantly higher percentage of WBCs with substantial PDL1 expression (P < 0.001). The percentage of PDL1 positive epithelial cells was not distinguishable between normal donor and patient samples. However increased post G1 epithelial cells ( > 5%) were observed in a majority of bladder cancer patients, with around 25% of samples showing a DNA index above 1.05. Conclusions: We developed a flow cytometry-based method to investigate PDL1 and DNA content simultaneously in cells from urine samples that could provide us with a new method to accurately identify bladder cancer patients through urine testing.
Volume
2019
Issue
37